Metrics Inc. now offers microbiology-testing services to the contract pharmaceutical industry
METRICS NOW OFFERS MICROBIOLOGY TESTING
New microbiology services part of $18-million facility expansion doubling Metrics' size
GREENVILLE, N.C.- Metrics Inc. now offers microbiology-testing services to the contract pharmaceutical industry.
The new services stem from the company's recent $18-million, 47,000-square-foot expansion that doubled its facility size and dramatically grew the company’s service capabilities to clients.
Metrics Inc., headquartered in Greenville, N.C., is one of the fastest-growing contract pharmaceutical development laboratories in the United States. Metrics provides quality pharmaceutical formulation, clinical trial material (Phase I, II and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.
"Offering our clients all the services they need under one roof has been a long-time goal for us," said Phil Hodges, president. "We're glad we can add value to the relationships we've developed with our clients, and know these services will make Metrics even more competitive when it comes to attracting new clients."
As part of its new microbiology laboratory, Metrics has brought antibiotic assay and sterility testing online, enhancing its ability to offer full microbiological support of sterile products. The company routinely performs bacterial endotoxin and particulate matter testing on parenterals.
Metrics' facility addition also includes four new fully operational analytical laboratories, validated and ready to handle projects; stability storage with state-of-the-art environmental specialties chambers complete with redundant mechanical systems and strictly limited personnel access; and a dedicated cytotoxic and potent compound laboratory.
For more information about Metrics, visit www.metricsinc.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.